In Chengdu, China, inside the orbit of West China Hospital and its very serious-looking cancer research machinery, scientists have been inventorying a new class of anti-lung-cancer tools that sound like they escaped from a Cold War spy novel: radionuclide-drug conjugates.
The name is a mouthful. Conveniently, the acronym is RDC, which is only slightly less intimidating and has the charm of a government form. But the idea is surprisingly elegant: attach a radioactive payload to a molecule that knows how to find cancer cells, then let it deliver radiation right where the trouble lives. Not to the whole neighborhood. Not to every innocent bystander cell trying to mind its own microscopic business. Ideally, to the tumor.
That is the dream, anyway. Biology, being biology, immediately asks for three forms of ID and then changes the locks.
The Delivery Van Has a Geiger Counter
Traditional radiation therapy usually comes from outside the body. Think of it as aiming a beam at a bad tenant through the wall. It can work very well, but nearby normal tissue may also get an unsolicited renovation.
RDCs flip the setup. They use a targeting piece, such as an antibody, peptide, small molecule, or nanoparticle, to carry a radionuclide into the body. The targeting piece is the address label. The radionuclide is the tiny radiation source. The linker and chelator are the engineering bits that keep the package from falling apart in transit, because apparently even molecular delivery systems can have supply-chain issues.
This approach belongs to the broader world of radiotheranostics, a wonderfully clunky word meaning therapy plus diagnostics. In plain English: first image where the drug goes, then treat what you can see. It is cancer care with GPS, assuming the GPS has not been dropped in a fountain.
Why Lung Cancer Needs Better GPS
Lung cancer remains the leading cause of cancer-related death worldwide, and part of the problem is that it is not one tidy disease wearing a name tag. Tumors differ from patient to patient, and even within one patient. Some cells respond to treatment. Others sit in the back wearing sunglasses, developing resistance like it is a professional certification.
The review by Liu and colleagues in Molecular Cancer maps the RDC landscape in lung cancer through January 2026. Their survey found 66 RDCs screened in lung cancer models or studies, with 30 already entering early-phase clinical trials [1]. That is not a stampede into routine care, but it is not a lonely laboratory curiosity either.
The field has also changed shape. Earlier work leaned on iodine-131 and yttrium-90 labeled antibodies. More recent clinical efforts have shifted toward lutetium-177 labeled peptides, especially those targeting somatostatin receptors, or SSTRs. SSTR sounds like a rejected airport code, but it matters because some lung cancers, especially neuroendocrine types, may display these receptors in ways that make them targetable.
Meanwhile, newer targets are drawing attention: fibroblast activation protein, EGFR, and PD-L1. Translation: researchers are no longer only staring at the cancer cell itself. They are also eyeing the tumor’s sketchy neighborhood, its support staff, and its fake security badges.
The Cool Part: See It, Then Zap It
The most appealing feature of RDCs is that they may help doctors answer two questions before committing to treatment: Does this patient’s tumor actually carry the target? And will enough of the drug reach the tumor without turning healthy organs into collateral paperwork?
That is where imaging radionuclides come in. PET or SPECT scans can show whether a target lights up. If it does, a therapeutic partner can potentially deliver radiation to the same biological address. This "treat what you see" concept already has real clinical momentum in neuroendocrine tumors and prostate cancer, with agents such as lutetium-177 DOTATATE and lutetium-177 PSMA-617 helping prove that targeted radiopharmaceuticals are not just decorative nuclear medicine confetti [2].
For lung cancer, the promise is still earlier. A 2023 review called radionuclide-based theranostics a promising strategy in lung cancer, while noting that target selection, tumor uptake, and toxicity remain stubborn problems [3]. A 2024 review of drug conjugates in lung cancer made a similar point from the broader conjugate-drug world: precision delivery helps, but resistance, penetration, and safety still get a vote [4].
The Problems Are Very On Brand for Cancer
RDCs face several unglamorous but serious hurdles. Off-target toxicity is one. If the radioactive payload accumulates in kidneys, bone marrow, liver, or other normal tissues, the "precision" part begins to look more aspirational than factual.
Radiation resistance is another. Cancer cells can repair DNA damage, hide in poorly oxygenated tumor regions, or use molecular escape routes because apparently tumors also read the fine print. Then there is radionuclide production. Some isotopes are hard to make, hard to ship, or hard to scale. Nothing says "future of medicine" like needing a cyclotron, a reactor, and the patience of a saint.
The review highlights possible next steps: better chelators to hold radionuclides securely, alpha emitters for more intense short-range damage, terbium-161 and other mixed-decay radionuclides, dual-targeting systems, pretargeting strategies, nanoparticles, personalized dosimetry, and combination therapy with immunotherapy or other drugs [1]. In other words, if the first molecular delivery van was useful, the next one may have better brakes, smarter routing, and fewer mysterious leaks.
What This Could Mean
If RDCs in lung cancer keep proving themselves in larger, carefully run trials, the real-world impact could be substantial. Patients might get scans that reveal whether a treatment is likely to work before they endure it. Doctors could tailor radiation dose to a person’s tumor and organs rather than using a one-size-fits-most approach, the medical equivalent of handing everyone the same hat.
For people with resistant or metastatic lung cancer, RDCs could add another precision tool to a crowded but still imperfect toolbox. Not magic. Not a cure-all. More like a very specialized locksmith for a disease that keeps changing the door.
Cancer biology remains absurdly complicated, because of course it does. But RDCs offer a compelling idea: use the tumor’s own molecular quirks as an address, deliver radiation from the inside, and maybe make lung cancer a little less good at being lung cancer. Modest goal. Terrible opponent. Worth the effort.
References
-
Liu J, Zuo X, Yang X, Wang X, Gan L, Xue J. Radionuclide-drug conjugates in lung cancer: advances in precision therapy and clinical translation. Molecular Cancer. 2026. https://doi.org/10.1186/s12943-026-02695-6
-
Zhang S, Wang X, Gao X, et al. Radiopharmaceuticals and their applications in medicine. Signal Transduction and Targeted Therapy. 2025;10:1. https://doi.org/10.1038/s41392-024-02041-6
-
Zhu T, Hsu JC, Guo J, Chen W, Cai W, Wang K. Radionuclide-based theranostics: a promising strategy for lung cancer. European Journal of Nuclear Medicine and Molecular Imaging. 2023;50:2353-2374. https://doi.org/10.1007/s00259-023-06174-8 PMCID: PMC10272099
-
Zhou L, Lu Y, Liu W, et al. Drug conjugates for the treatment of lung cancer: from drug discovery to clinical practice. Experimental Hematology & Oncology. 2024;13:26. https://doi.org/10.1186/s40164-024-00493-8
-
Lu X, Zhu Y, Deng X, et al. Development of a supermolecular radionuclide-drug conjugate system for integrated radiotheranostics for non-small cell lung cancer. Journal of Medicinal Chemistry. 2024;67:11152-11167. https://doi.org/10.1021/acs.jmedchem.4c00673
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.